Lauren is currently taking disease modifying anti-rheumatic drugs
(DMARDs) to control her condition, however she still experiences fatigue and pain towards the end of the day.
Roche announced today that the subcutaneous formulation of RoACTEMRA (tocilizumab) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the treatment of moderate to severe active rheumatoid arthritis (RA) in patients who have either responded inadequately to, or who are intolerant to, previous therapy with one or more disease modifying anti-rheumatic drugs
(DMARDs) or tumour necrosis factor (TNF) inhibitors.
compile 28 chapters for scientists and clinicians that detail the process and factors that influence chronic inflammation, outlining the systems biology of inflammation and regulatory mechanisms, including initiation, progression, and resolution; associated pathologies, such as cancer, chronic wounds, scarring, neuroinflammatory disease, autoimmune disease, and vascular inflammation; and nutrition and therapeutics for these diseases, including the protective abilities of structurally diverse antioxidants, phytochemicals, anti-inflammatory diets, omega-3 fatty acids, nonsteroidal anti-inflammatory drugs (NSAIDS), physical activity, disease modifying anti-rheumatic drugs
, and novel regimens.
People with rheumatoid arthritis often have to take anti-inflammatory drugs alongside disease modifying anti-rheumatic drugs
to combat the symptoms of their rheumatoid arthritis and taken long term, this type of medication can have unpleasant side-effects," said Ailsa Bosworth, chief executive at the National Rheumatoid Arthritis Society.
Table 4-1: Selected Prescription Disease Modifying Anti-Rheumatic Drugs
As with other disease modifying anti-rheumatic drugs
, serious infections have been reported in some patients treated with Actemra.
Rheumatoid arthritis plus hepatitis C provides a difficult treatment dilemma due to the potential hepatotoxicity of most conventional disease modifying anti-rheumatic drugs
It is a new drug in the category of Disease Modifying Anti-rheumatic Drugs
("DMARDS"), and will be primarily used in the treatment of active rheumatoid arthritis.
Rigel has focused its rheumatoid arthritis (RA) program on the development of oral, safe, disease modifying anti-rheumatic drugs
Rigel has focused its RA program on the development of oral, safe, disease modifying anti-rheumatic drugs
This briefing is based upon ongoing Healthcare industry analysis and it will benefit pharmaceutical companies that already participate in the segments related to RA, namely COX-2 inhibitors and other non-steroidal drugs (NSAIDs), disease modifying anti-rheumatic drugs
(DMARDs) and biologic response modifiers (BRMs) as well as companies intended to enter in those segments in Brazil.
Rigel has focused its rheumatoid arthritis program on the development of oral, safe, disease modifying anti-rheumatic drugs